Eloxx Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Eloxx Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eloxx Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eloxx Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Eloxx Pharmaceuticals Inc (Eloxx Pharmaceuticals) is a biopharmaceutical company focused on developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. Targeting ribosome subunits provides a therapeutic approach to addressing a number of genetic diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Eloxx Pharmaceuticals is actively engaged in research and development initiatives focused on advancing its portfolio of novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations. The primary focus is on developing exaluren, a novel eukaryotic ribosome-selective glycoside product candidate, for the treatment of Alport syndrome and other rare diseases driven by nonsense mutations. Additionally, the company is collaborating with Almirall, SA to develop ZKN-013, an oral ribosome modulating agent for the treatment of recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. Eloxx Pharmaceuticals is also evaluating and executing strategic partnerships to maximize the potential of its compound library. The R&D facility of Eloxx Pharmaceuticals is located in Rehovot, Israel. This facility supports the company's research initiatives and development programs. The company maintains a robust patent portfolio with 66 issued patents and 101 pending patent applications, and is developing key pipeline products such as exaluren and ZKN-013. In FY2025, the company incurred an expense US$3.1 million on its research and development activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer